Microbiota and probiotics in health and HIV infection

Nutrients

Volumn 9, Issue 6, 2017, Pages

  D’Angelo, Chiara ^a   Reale, Marcella ^a   Costantini, Erica ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Dietary supplements; HIV; Inflammation; Microbiome; Nutrition; Probiotics

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; IMMUNOGLOBULIN A; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ANTIGEN PRESENTING CELL; ANTIRETROVIRAL THERAPY; BACTERIAL COLONIZATION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DYSBIOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFLAMMATION; INTESTINAL BARRIER; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN EXPRESSION; REVIEW; MICROBIOLOGY;

GASTROINTESTINAL MICROBIOME; HIV INFECTIONS; HUMANS; PROBIOTICS;

EID: 85020841974     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9060615     Document Type: Review

References (130)

1. Parker, R.B. Probiotics, the other half of the antibiotics story. Anim. Nutr. Health 1974, 29, 4-8.
2. Fuller, R. Probiotics in man and animals. J. Appl. Bacteriol. 1989, 66, 365-378.
3. Salminen, S., von Wright, A., Morelli, L., Marteau, P., Brassart, D., de Vos, W.M., Fonden, R., Saxelin, M., Collins, K., Mogensen, G., et al. Demonstration of safety of probiotics—A review. Int. J. Food Microbiol. 1998, 44, 93-106.
4. Yan, F., Polk, D.B. Probiotics and immune health. Curr. Opin. Gastroenterol. 2011, 27, 496-501.
5. Kang, H.J., Im, S.H. Probiotics as an immune modulator. J. Nutr. Sci. Vitaminol. 2015, 61, 103-105.
6. O’Toole, P.W., Cooney, J.C. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip. Perspect. Infect. Dis. 2008, 2008, 175285.
7. Sanders, M.E. Impact of probiotics on colonizing microbiota of the gut. J. Clin. Gastroenterol. 2011, 45, 115-119.
8. Ganji-Arjenaki, M., Rafieian-Kopaei, M. Probiotics are a good choice in remission of inflammatory bowel diseases: A meta-analysis and systematic review. J. Cell Physiol. 2017.
9. Yoo, J.Y., Kim, S.S. Probiotics and prebiotics: Present status and future perspectives on metabolic disorders. Nutrients 2016, 8, 173.
10. Guandalini, S. Probiotics for prevention and treatment of diarrhea. J. Clin. Gastroenterol. 2011, 45, 149-153.
11. Sheil, B., Shanahan, F., O’Mahony, L. Probiotic effects on inflammatory bowel disease. J. Nutr. 2007, 137, 819-824.
12. Yang, G., Liu, Z., Yang, P.C. Treatment of allergic rhinitis with probiotics: An alternative approach. N. Am. J. Med. Sci. 2013, 5, 465-468.
13. Wang, Y., Li, X., Ge, T., Xiao, Y., Liao, Y., Cui, Y., Zhang, Y., Ho, W., Yu, G., Zhang, T. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine 2016, 95, 4509.
14. Claesson, M.J., Jeffery, I.B., Conde, S., Power, S.E., O’Connor, E.M., Cusack, S., Harris, H.M., Coakley, M., Lakshminarayanan, B., O’Sullivan, O., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012, 488, 178-184.
15. Bailey, M.T. Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation? Brain Behav. Immun. 2011, 25, 397.
16. Moreira, A.P., Texeira, T.F., Ferreira, A.B., Peluzio Mdo, C., Alfenas Rde, C. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br. J. Nutr. 2012, 108, 801-809.
17. Brenchley, J.M., Douek, D.C. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008, 1, 23-30.
18. Kotler, D.P. HIV infection and the gastrointestinal tract. AIDS 2005, 19, 107-117.
19. Brenchley, J.M., Schacker, T.W., Ruff, L.E., Price, D.A., Taylor, J.H., Beilman, G.J., Nguyen, P.L., Khoruts, A., Larson, M., Haase, A.T., et al. CD4+ T-cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004, 200, 749-759.
20. Dillon, S.M., Frank, D.N., Wilson, C.C. The gut microbiome and HIV-1 pathogenesis: A two-way street. AIDS 2016, 30, 2737-2751.
21. Liu, J., Williams, B., Frank, D., Dillon, S.M., Wilson, C.C., Landay, A.L. Inside Out: HIV, the gut microbiome, and the mucosal immune system. J. Immunol. 2017, 198, 605-614.
22. Mudd, J.C., Brenchley, J.M. Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression. J. Infect. Dis. 2016, 214, 58-66.
23. Hamza, O.J., Matee, M.I., Simon, E.N., Kikwilu, E., Moshi, M.J., Mugusi, F., Mikx, F.H., Verweij, P.E., van der Ven, A.J. Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health 2006, 6, 12-20.
24. Vujkovic-Cvijin, I., Dunham, R.M., Iwai, S., Maher, M.C., Albright, R.G., Broadhurst, M.J., Hernandez, R.D., Lederman, M.M., Huang, Y., Somsouk, M., et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci. Transl. Med. 2013, 5, 193ra91.
25. Nowak, P., Troseid, M., Avershina, E., Barqasho, B., Neogi, U., Holm, K., Hov, J.R., Noyan, K., Vesterbacka, J., Svärd, J., et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 2015, 29, 2409-2418.
26. Carter, G.M., Esmaeili, A., Shah, H., Indyk, D., Johnson, M., Andreae, M., Sacks, H.S. Probiotics in Human Immunodeficiency Virus Infection: A systematic review and evidence synthesis of benefits and risks. Open Forum Infect. Dis. 2016, 3, ofw164.
27. Klatt, N.R., Canary, L.A., Canary, L.A., Sun, X., Vinton, C.L., Funderburg, N.T., Morcock, D.R., Quiñones, M., Deming, C.B., Perkins, M., et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J. Clin. Investig. 2013, 123, 903-907.
28. Gori, A., Rizzardini, G., Van’t Land, B., Amor, K.B., van Schaik, J., Torti, C., Quirino, T., Tincati, C., Bandera, A., Knol, J., et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naïve HIV-infected adults: Results of the “COPA” pilot randomized trial. Nature 2011, 4, 554-563.
29. Ohland, C.L., MacNaughton, W.K. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G807-G819.
30. Delcenserie, V., Martel, D., Lamoureux, M., Amiot, J., Boutin, Y., Roy, D. Immunomodulatory effects of probiotics in the intestinal tract. Curr. Issues Mol. Biol. 2008, 10, 37-54.
31. Rijkers, G.T., Bengmark, S., Enck, P., Haller, D., Herz, U., Kalliomaki, M., Kudo, S., Lenoir-Wijnkoop, I., Mercenier, A., Myllyluoma, E., et al. Guidance for substantiating the evidence for beneficial effects of probiotics: Current status and recommendations for future research. J. Nutr. 2010, 140, 671S-676S.
32. Cinque, B., La Torre, C., Lombardi, F., Palumbo, P., Evtoski, Z., Santini, S.J., Falone, S., Cimini, A., Amicarelli, F., Cifone, M.G. Vsl#3 probiotic differently influence iec-6 intestinal epithelial cell status and function. J. Cell. Physiol. 2017.
33. Allen, S.J., Martinez, E.G., Gregorio, G.V., Dans, L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst. Rev. 2010, 11, CD003048.
34. Hooper, L.V., Littman, D.R., Macpherson, A.J. Interactions between the microbiota and the immune system. Science 2012, 336, 1268-1273.
35. Buffie, C.G., Pamer, E.G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 2013, 13, 790-801.
36. Bäumler, A.J., Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016, 535, 85-93.
37. Baquero, F., Nombela, C. The microbiome as a human organ. Clin. Microbiol. Infect. 2012, 18, 2-4.
38. Nishio, J., Honda, K. Immunoregulation by the gut microbiota. Cell. Mol. Life Sci. 2012, 69, 3635-3650.
39. Peterson, L.W., Artis, D. Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 2014, 14, 141-153.
40. Garrett, W.S., Gordon, J.I., Glimcher, L.H. Homeostasis and inflammation in the intestine. Cell 2010, 140, 859-870.
41. Yuan, B., Zhou, S., Lu, Y., Liu, J., Jin, X., Wan, H., Wang, F. Changes in the expression and distribution of claudins, increased epithelial apoptosis, and a mannan-binding lectin-associated immune response lead to barrier dysfunction in dextran sodium sulfate-induced rat colitis. Gut Liver 2015, 9, 734-740.
42. Nakamura, K., Sakuragi, N., Takakuwa, A., Ayabe, T. Paneth cell α-defensins and enteric microbiota in health and disease. Biosci. Microbiota Food Health 2016, 35, 57-67.
43. Kucharzik, T., Lugering, N., Rautenberg, K., Lugering, A., Schmidt, M.A., Stoll, R., Domschke, W. Role of M-cells in intestinal barrier function. Ann. N. Y. Acad. Sci. 2000, 915, 171-183.
44. Zeuthen, L. H., Fink, L. N., Frokiaer, H. Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor β. Immunology 2008, 123, 197-208.
45. Baba, N., Samson, S., Bourdet-Sicard, R., Rubio, M., Sarfati, M. Commensal bacteria trigger a full dendritic cell maturation program that promotes the expansion of non-Tr1 suppressor T-cells. J. Leukoc. Biol. 2008, 84, 468-476.
46. Kim, Y.S., Ho, S.B. Intestinal goblet cells and mucins in health and disease: Recent insights and progress. Curr. Gastroenterol. Rep. 2010, 12, 319-330.
47. Rogier, R., Koenders, M.I., Abdollahi-Roodsaz, S. Toll-like receptor mediated modulation of T-cell response by commensal intestinal microbiota as a trigger for autoimmune. Arthritis 2015, 2015, 527696.
48. Abreu, M.T. Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes intestinal function. Nat. Rev. Immunol. 2010, 11, 215.
49. Cario, E., Gerken, G., Podolsky, D. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenerology 2004, 127, 224-238.
50. Melmed, G., Thomas, L.S., Lee, N., Tesfay, S.Y., Lukasek, K., Michelsen, K.S., Hou, Y., Hu, B., Arditi, M., Abreu, M.T. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: Implications for host-microbial interactions in the gut. J. Immunol. 2003, 170, 1406-1415.
51. Ashida, H., Ogawa, M., Kim, M., Mimuro, H., Sasakawa, C. Bacteria and host interactions in the gut epithelial barrier. Nat. Chem. Biol. 2012, 8, 36-45.
52. Caricilli, A.M., Castoldi, A., Câmara, N.O. Intestinal barrier: A gentlemen's agreement between microbiota and immunity. World J. Gastrointest. Pathophysiol. 2014, 5, 18-32.
53. Ahrne, S., Hagslatt, M.L. Effect of lactobacilli on paracellular permeability in the gut. Nutrients 2011, 3, 104-117.
54. Ferreira, C.M., Vieira, A.T., Vinolo, M.A., Oliveira, F.A., Curi, R., Martins, F.S. The central role of the gut microbiota in chronic inflammatory diseases. J. Immunol. Res. 2014, 689492.
55. Rao, R.K., Samak, G. Protection and Restitution of gut barrier by probiotics: Nutritional and clinical implications. Curr. Nutr. Food Sci. 2013, 9, 99-107.
56. Bron, P.A., Kleerebezem, M., Brummer, R.J., Cani, P.D., Mercenier, A., MacDonald, T.T., Garcia-Ródenas, C.L., Wells, J.M. Can probiotics modulate human disease by impacting intestinal barrier function? Br. J. Nutr. 2017, 117, 93-107.
57. Abedi, D., Feizizadeh, S., Akbari, S., Jafarian-Dehkordi, A. In vitro anti-bacterial and anti-adherence effects of Lactobacillus delbrueckii subsp bulgaricus on Escherichia coli. Res. Pharm. Sci. 2013, 8, 260-268.
58. Ribet, D., Cossart, P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes Infect. 2015, 17, 173-183.
59. Coombes, J.L., Powrie, F. Dendritic cells in intestinal immune regulation. Nat. Rev. Immunol. 2008, 8, 435-446.
60. Van de Veerdonk, F.L., Gresnigt, M.S., Kullberg, B.J., van der Meer, J.W., Joosten, L.A., Netea, M.G. Th17 responses and host defense against microorganisms: An overview. BMB Rep. 2009, 42, 776-787.
61. Donkor, O.N., Ravikumar, M., Proudfoot, O., Day, S.L., Apostolopoulos, V., Paukovics, G., Vasiljevic, T., Nutt, S.L., Gill, H. Cytokine profile and induction of T helper type 17 and regulatory T-cells by human peripheral mononuclear cells after microbial exposure. Clin. Exp. Immunol. 2012, 167, 282-295.
62. Symons, A., Budelsky, A.L., Towne, J.E. Are Th17 cells in the gut pathogenic or protective? Mucosal Immunol. 2012, 5, 4-6.
63. Ouyang, W., Kolls, J.K., Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28, 454-467.
64. Bettelli, E., Korn, T., Oukka, M., Kuchroo, V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453, 1051-1057.
65. Liang, S.C., Tan, X.Y., Luxenberg, D.P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., Fouser, L.A. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 2006, 203, 2271-2279.
66. Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M. Regulatory T-cells and immune tolerance. Cell 2008, 133, 775-787.
67. Mathias, A., Pais, B., Favre, L., Benyacoub, J., Corthésy, B. Role of secretory IgA in the mucosal sensing of commensal bacteria. Gut Microbes 2014, 5, 688-695.
68. Sharma, R., Young, C., Neu, J. Molecular modulation of intestinal epithelial barrier: Contribution of microbiota. J. Biomed. Biotechnol. 2010, 305879.
69. Tincati, C., Douek, D.C., Marchetti, G. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res. Ther. 2016, 13, 19.
70. Neild, P.J., Nijran, K.S., Yazaki, E., Evans, D.F., Wingate, D.L., Jewkes, R., Gazzard, B.G. Delayed gastric emptying in human immunodeficiency virus infection: Correlation with symptoms, autonomic function, and intestinal motility. Dig. Dis. Sci. 2000, 45, 1491-1499.
71. Mutlu, E.A., Keshavarzian, A., Losurdo, J., Swanson, G., Siewe, B., Forsyth, C., French, A., Demarais, P., Sun, Y., Koenig, L., et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014, 10, e1003829.
72. Lozupone, C.A., Li, M., Campbell, T.B., Flores, S.C., Linderman, D., Gebert, M.J., Knight, R., Fontenot, A.P., Palmer, B.E. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 2013, 14, 329-339.
73. Dillon, S.M., Lee, E.J., Kotter, C.V., Austin, G.L., Dong, Z., Hecht, D.K., Gianella, S., Siewe, B., Smith, D.M., Landay, A.L., et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014, 7, 983-994.
74. Perez-Santiago, J., Gianella, S., Massanella, M., Spina, C.A., Karris, M.Y., Var, S.R., Patel, D., Jordan, P.S., Young, J.A., Little, S.J., et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS 2013, 27, 1921-1931.
75. Nwosu, F.C., Avershina, E., Wilson, R., Rudi, K. Gut microbiota in HIV Infection: Implication for disease progression and management. Gastroenterol. Res. Pract. 2014, 2014, 803185.
76. Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 2006, 12, 1365-1371.
77. Assimakopoulos, S.F., Dimitropoulou, D., Marangos, M., Gogos, C.A. Intestinal barrier dysfunction in HIV infection: Pathophysiology, clinical implications and potential therapies. Infection 2014, 42, 951-959.
78. Lapenta, C., Boirivant, M., Marini, M., Santini, S.M., Logozzi, M., Viora, M., Belardelli, F., Fais, S. Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur. J. Immunol. 1999, 29, 1202-1208.
79. Steele, A.K., Lee, E.J., Manuzak, J.A., Dillon, S.M., Beckham, J.D., McCarter, M.D., Santiago, M.L., Wilson, C.C. Microbial exposure alters HIV-1-induced mucosal CD4+ T-cell death pathways ex vivo. Retrovirology 2014, 11, 14.
80. Doitsh, G., Galloway, N.L., Geng, X., Yang, Z., Monroe, K.M., Zepeda, O., Hunt, P.W., Hatano, H., Sowinski, S., Munoz-Arias, I., et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014, 505, 509-514.
81. French, M., Keane, N., McKinnon, E., Phung, S., Price, P. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T-cells and B cells. HIV Med. 2007, 8, 148-155.
82. Singh, A., Vajpayee, M., Ali, S.A., Mojumdar, K., Chauhan, N.K., Singh, R. HIV-1 diseases progression associated with loss of Th17 cells in subtype ‘C’ infection. Cytokine 2012, 60, 55-63.
83. + T-cells are detectable in early human immunodeficiency virus type 1 infection. J. Virol. 2008, 82, 6767-6771.
84. Ancuta, P., Monteiro, P., Sekaly, R.P. Th17 lineage commitment and HIV-1 pathogenesis. Curr. Opin. HIV AIDS 2010, 5, 158-165.
85. Lindemans, C.A., Calafiore, M., Mertelsmann, A.M., O’Connor, M.H., Dudakov, J.A., Jenq, R.R., Velardi, E., Young, L.F., Smith, O.M., Lawrence, G., et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature 2015, 528, 560-564.
86. Dandekar, S., George, M.D., Baumler, A.J. Th17 cells, HIV and the gut mucosal barrier. Curr. Opin. HIV AIDS 2010, 5, 173-178.
87. Chege, D., Sheth, P.M., Kain, T., Kim, C.J., Kovacs, C., Loutfy, M., Halpenny, R., Kandel, G., Chun, T.W., Ostrowski, M., et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 2011, 25, 741-749.
88. Hunt, P.W. Th17, gut, and HIV: Therapeutic implications. Curr. Opin. HIV AIDS 2010, 5, 189-193.
89. Hartigan-O’Connor, D.J., Hirao, L.A., McCune, J.M., Dandekar, S. Th17 cells and regulatory T-cells in elite control over HIV and SIV. Curr. Opin. HIV AIDS 2011, 6, 221-227.
90. Kanwar, B., Favre, D., McCune, J.M. Th17 and regulatory T-cells: Implications for AIDS pathogenesis. Curr. Opin. HIV AIDS 2010, 5, 151-157.
91. Brandt, L., Benfield, T., Mens, H., Clausen, L.N., Katzenstein, T.L., Fomsgaard, A., Karlsson, I. Low level of regulatory T-cells and maintenance of balance between regulatory T-cells and TH17 cells in HIV-1-infected elite controllers. J. Acquir. Immune Defic. Syndr. 2011, 57, 101-108.
92. Chevalier, M.F., Weiss, L. The split personality of regulatory T-cells in HIV infection. Blood 2013, 121, 29-37.
93. Neuhaus, J., Jacobs, D.R., Jr., Baker, J.V., Calmy, A., Duprez, D., La Rosa, A., Kuller, L.H., Pett, S.L., Ristola, M., Ross, M.J., et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 2010, 201, 1788-1795.
94. Sankaran, S., George, M.D., Reay, E., Guadalupe, M., Flamm, J., Prindiville, T., Dandekar, S. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J. Virol. 2008, 82, 538-545.
95. Hunt, P.W., Sinclair, E., Rodriguez, B., Shive, C., Clagett, B., Funderburg, N., Robinson, J., Huang, Y., Epling, L., Martin, J.N., et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J. Infect. Dis. 2014, 210, 1228-1238.
96. Rajasuriar, R., Wright, E., Lewin, S.R. Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Curr. Opin. HIV AIDS 2015, 10, 35-42.
97. Bolsewicz, K., Debattista, J., Vallely, A., Whittaker, A., Fitzgerald, L. Factors associated with antiretroviral treatment uptake and adherence: A review. Perspectives from Australia, Canada, and the United Kingdom. AIDS Care 2015, 27, 1429-1438.
98. Pham, M.D., Romero, L., Parnell, B., Anderson, D.A., Crowe, S.M., Luchters, S. Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: A systematic. AIDS Res. Ther. 2017, 14, 3.
99. Katlama, C., Deeks, S.G., Autran, B., Martinez-Picado, J., van Lunzen, J., Rouzioux, C., Miller, M., Vella, S., Schmitz, J.E., Ahlers, J., et al. Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs. Lancet 2013, 381, 2109-2117.
100. Hummelen, R., Vos, A.P., van’t Land, B., van Norren, K., Reid, G. Altered host-microbe interaction in HIV: A target for intervention with pro-and pre-biotics. Int. Rev. Immunol. 2010, 29, 485-513.
101. D’Ettorre, G., Ceccarelli, G., Giustini, N., Serafino, S., Calantone, N., De Girolamo, G., Bianchi, L., Bellelli, V., Ascoli-Bartoli, T., Marcellini, S., et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: Results of the “Probio-HIV” clinical trial. PLoS ONE 2015, 10.
102. Surendran Nair, M., Amalaradjou, M.A., Venkitanarayanan, K. Antivirulence properties of probiotics in combating microbial pathogenesis. Adv. Appl. Microbiol. 2017, 98, 1-29.
103. Falasca, K., Vecchiet, J., Ucciferri, C., Di Nicola, M., D’Angelo, C., Reale, M. Effect of probiotic supplement on cytokine levels in HIV-infected individuals: A preliminary study. Nutrients 2015, 7, 8335-8347.
104. Hardy, H., Harris, J., Lyon, E., Beal, J., Foey, A.D. Probiotics, prebiotics and immunomodulation of gut mucosal defences: Homeostasis and immunopathology. Nutrients 2013, 5, 1869-1912.
105. Tanabe, S. The effect of probiotics and gut microbiota on Th17 cells. Int. Rev. Immunol. 2013, 32, 511-525.
106. + T-cells by probiotics administration suppresses immune disorders. Proc. Natl. Acad. Sci. USA 2010, 107, 2159-2164.
107. López, P., González-Rodríguez, I., Gueimonde, M., Margolles, A., Suárez, A. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS ONE 2011, 6, e24776.
108. Kim, C.J., Walmsley, S.L., Raboud, J.M., Kovacs, C., Coburn, B., Rousseau, R., Reinhard, R., Rosenes, R., Kaul, R. Can probiotics reduce inflammation and enhance gut immune health in people living with HIV: Study designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials. HIV Clin. Trials 2016, 17, 147-157.
109. Cunningham-Rundles, S., Ahrne, S., Johann-Liang, R., Abuav, R., Dunn-Navarra, A.M., Grassey, C., Bengmark, S., Cervia, J.S. Effect of probiotic bacteria on microbial host defense, growth, and immune function in human immunodeficiency virus type-1 infection. Nutrients 2011, 3, 1042-1070.
110. Yang, O.O., Kelesidis, T., Cordova, R., Khanlou, H. Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial. AIDS Res. Hum. Retrovir. 2014, 30, 988-995.
111. Irvine, S.L., Hummelen, R., Hekmat, S., Looman, C.W., Habbema, J.D., Reid, G. Probiotic yogurt consumption is associated with an increase of CD4 count among people living with HIV/AIDS. J. Clin. Gastroenterol. 2010, 44, 201-205.
112. Iwabuchi, N., Takahashi, N., Xiao, J.Z. Suppressive effects of Bifidobacterium longum on the production of Th2-attracting chemokines induced with T-cell-antigen-presenting cell interactions. FEMS Immunol. Med. Microbiol. 2009, 55, 324-334.
113. Mirmonsef, P., Krass, L., Landay, A., Spear, G.T. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr. HIV Res. 2012, 10, 202-210.
114. Hummelen, R., Changalucha, J., Butamanya, N.L., Cook, A., Habbema, J.D., Reid, G. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. Int. J. Gynaecol. Obstet. 2010, 111, 245-248.
115. Staab, B., Eick, S., Knöfler, G., Jentsch, H. The influence of a probiotic milk drink on the development of gingivitis: A pilot study. J. Clin. Periodontol. 2009, 36, 850-856.
116. Ryder, M.I., Nittayananta, W., Coogan, M., Greenspan, D., Greenspan, J.S. Periodontal disease in HIV/AIDS. Periodontology 2000 2012, 60, 78-97.
117. Gupta, G. Probiotics and periodontal health. J. Med. Life 2011, 4, 387-394.
118. Noguera-Julian, M., Guillén, Y., Peterson, J., Reznik, D., Harris, E.V., Joseph, S.J., Rivera, J., Kannanganat, S., Amara, R., Nguyen, M.L., et al. Oral microbiome in HIV-associated periodontitis. Medicine 2017, 96, e5821.
119. Martinez, R.C., Bedani, R., Saad, S.M. Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. Br. J. Nutr. 2015, 114, 1993-2015.
120. Forsberg, A., West, C.E., Prescott, S.L., Jenmalm, M.C. Pre-and probiotics for allergy prevention: Time to revisit recommendations? Clin. Exp. Allergy 2016, 46, 1506-1521.
121. Parvez, S., Malik, K.A., Ah Kang, S., Kim, H.Y. Probiotics and their fermented foods products are beneficial for health. J. Appl. Microbiol. 2006, 100, 1171-1185.
122. Isolauri, E. Probiotics in human disease. Am. J. Clin. Nutr. 2001, 73, 1142S-1146S.
123. Rajasuriar, R., Khoury, G., Kamarulzaman, A., French, M.A., Cameron, P.U., Lewin, S.R. Persistent immune activation in chronic HIV infection: Do any interventions work? AIDS 2013, 27, 1199-1208.
124. González-Hernández, L.A., Jave-Suarez, L.F., Fafutis-Morris, M., Montes-Salcedo, K.E., Valle-Gutierrez, L.G., Campos-Loza, A.E., Enciso-Gómez, L.F., Andrade-Villanueva, J.F. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: A double-blind randomized controlled pilot trial. Nutr. J. 2012, 11, 90.
125. Amara, A.A., Shibl, A. Role of Probiotics in health improvement, infection control and disease treatment and management. Saudi Pharm. J. 2015, 23, 107-114.
126. Connolly, N.C., Riddler, S.A., Rinaldo, C.R. Proinflammatory cytokines in HIV disease—A review and rationale for new therapeutic approaches. AIDS Rev. 2005, 7, 168-180.
127. Merlini, E., Bai, F., Bellistri, G.M., Tincati, C., d’Arminio Monforte, A., Marchetti, G. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS ONE 2011, 6, e18580.
128. Gad, M., Ravn, P., Søborg, D.A., Lund-Jensen, K., Ouwehand, A.C., Jensen, S.S. Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. FEMS Immunol. Med. Microbiol. 2011, 63, 93-107.
129. Sánchez, B., Delgado, S., Blanco-Míguez, A., Lourenço, A., Gueimonde, M., Margolles, A. Probiotics, gut microbiota, and their influence on host health and disease. Mol. Nutr. Food Res. 2017, 61.
130. Hempel, S., Newberry, S., Ruelaz, A., Wang, Z., Miles, J., Suttorp, M.J., Johnsen, B., Shanman, R., Slusser, W., Fu, N., et al. Safety of probiotics to reduce risk and prevent or treat disease. Evid. Rep. Technol. Assess 2011, 200, 1-645.